Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Pharmaceutical Drug Delivery Market analysis

The UK Pharmaceutical Drug Delivery Market was valued at $321810 Million in 2026 and projected to reach to $338090 Million by 2031, representing a compound annual growth rate of CAGR 1.9%. The UK pharmaceutical drug delivery market is positioned for steady growth over the forecast period, supported by an aging population requiring chronic disease management and increased NHS investment in innovative therapies.

UK Pharmaceutical Drug Delivery Market Trends and Insights

  • The US market reflects a mature healthcare landscape with established regulatory frameworks and advanced manufacturing capabilities that support steady expansion in drug delivery technologies.
  • The US pharmaceutical sector continues to invest in innovative delivery mechanisms, including biologics, injectables, and oral formulations, driven by aging demographics and chronic disease prevalence. Growth in the US market is characterized by moderate but consistent expansion, with the US benefiting from strong healthcare infrastructure and significant R&D investments from pharmaceutical manufacturers.
  • Between 2026 and 2031, the US is expected to maintain its position as a leading market for drug delivery solutions, supported by reimbursement policies and patient demand for improved therapeutic outcomes.
  • The US market's slower growth rate compared to global averages reflects market maturity, yet the US continues to drive innovation in personalized medicine and advanced delivery platforms..

Key Market Statistics

  • CAGR (2026-2031) CAGR 1.9%
  • Market Size, 2026 ~USD 321810 Million
  • Forecast, 2031 ~USD 338090 Million
  • Country UK

UK Pharmaceutical Drug Delivery Market Overview

Market Valuation :

The UK pharmaceutical drug delivery market is valued at $321.81 billion in 2026, demonstrating the country's significant position within the European healthcare sector and its advanced pharmaceutical infrastructure.

Growth Trajectory :

The UK market is projected to reach $338.09 billion by 2031, with a CAGR of 1.9%, reflecting steady expansion driven by aging demographics, chronic disease prevalence, and continued investment in healthcare innovation.

Regulatory Environment :

The UK benefits from a robust regulatory framework post-Brexit, with the MHRA maintaining stringent quality standards that support innovation in drug delivery technologies while ensuring patient safety and efficacy.

Technology Adoption :

UK pharmaceutical companies are increasingly adopting advanced drug delivery systems including biologics, injectables, and personalized medicine platforms, supported by strong R&D capabilities and academic partnerships.

UK Pharmaceutical Drug Delivery Market Dynamics

  • The market benefits from established manufacturing capabilities, strong intellectual property protections, and collaborative relationships between pharmaceutical companies and research institutions.
  • Regulatory clarity through the MHRA and alignment with international standards facilitate market entry and product development.
  • However, growth remains moderate compared to global markets, reflecting market maturity and pricing pressures from healthcare cost containment initiatives.
  • Strategic opportunities exist in specialty pharmaceuticals, biosimilars, and advanced delivery mechanisms targeting unmet clinical needs..

Related Ecosystem

Drug Delivery Devices

Top Technologies
  • Disposable Autoinjectors
  • Reusable Autoinjectors
  • Insulin Pumps
  • Pen Injectors
  • Transdermal Patches
Top Companies
  • Novo nordisk a/s
  • Becton, Dickinson and Company
  • Terumo Corporation
  • Medtronic plc
  • Nipro Corporation

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Stryker Corporation
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • The US pharmaceutical drug delivery market is valued at $321.81 billion in 2026 with a projected value of $338.09 billion by 2031.
      • The US market exhibits a 1.9% CAGR, reflecting a mature but stable healthcare sector with consistent demand for advanced delivery technologies.
      • The US benefits from robust regulatory frameworks, strong healthcare infrastructure, and significant pharmaceutical R&D investments that support market growth.
      • The US market is driven by aging demographics, chronic disease prevalence, and increasing demand for personalized medicine and innovative delivery platforms.

      Pharmaceutical Drug Delivery Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment CHINA (Route Of Administration)
      Forecast Period 2026–2031
      Growth Rate CAGR of 6.3% from 2026 to 2031
      Largest Segment SOLID ORAL DRUGS (Type)
      Market Size Base Year (Billions) ~USD 2153.45 (2026)
      Revenue Forecast (Billions) ~USD 2922.82 (2031)
      Segments Covered Dosage Form, Type, Application, Facility Of Use, Material, Product, Usability, Route Of Administration

      UK Pharmaceutical Drug Delivery Market Report Segmentation

      8 segment dimensions are covered across the global market.

      By Dosage Form

      • Capsules
      • Creams
      • Elixirs
      • Elixis
      • Emulsion
      • Emulsions
      • Eye Drops
      • Eye Ointments
      • Gels
      • Liquid Ocular Sprays
      • Liquid Oral Drugs
      • Lotions
      • Nasal Drops
      • Nasal Gels
      • Nasal Powders
      • Nasal Sprays
      • Ointments
      • Pastes
      • Pates
      • Pills
      • Powders
      • Semi-Solid Oral Drugs
      • Solid Oral Drugs
      • Solutions
      • Suppositories
      • Suspensions
      • Syrups
      • Tablets

      By Type

      • Active
      • Autoinjectors
      • Buccal Drug Delivery
      • Conventional Injection Devices
      • Drug-Coated Contact Lenses
      • Dry Powder Inhalers
      • Emulsion
      • Gels
      • Jet Nebulizers
      • Liquid Ocular Formulations
      • Liquid Topical Formulations
      • Metered-Dose Inhalers
      • Nebulizers
      • Needle-Free Injectors
      • Ocular Devices
      • Ocular Inserts
      • Oral Transmucosal Formulations
      • Other Transmucosal Formulations
      • Passive
      • Patches
      • Pen Injectors
      • Rectal Drug Delivery
      • Self-Injection Devices
      • Semi-Solid Ocular Formulations
      • Semi-Solid Topical Formulations
      • Soft Mist Nebulizers
      • Solid Topical Formulations
      • Solutions
      • Sprays
      • Sublingual Drug Delivery
      • Suspensions
      • Transdermal Products
      • Ultrasonic Nebulizers
      • Vaginal Drug Delivery
      • Wearable Injectors

      By Application

      • Autoimmune Diseases
      • Cancer
      • Cns Disorders
      • Cvd
      • Diabetes
      • Infectious Diseases
      • Other Applications
      • Respiratory Diseases

      By Facility Of Use

      • Ascs/ Clinics
      • Ascs/Clinics
      • Diagnostic Centers
      • Home Care Settings
      • Hospitals
      • Other Facilities Of Use

      By Material

      • Glass Syringes
      • Plastic Syringes

      By Product

      • Fillable Syringes
      • Prefilled Syringes

      By Usability

      • Disposable Syringes
      • Reusable Syringes

      By Route Of Administration

      • Implantable Drug Delivery
      • Injectable Drug Delivery
      • Nasal Drug Delivery
      • Ocular Drug Delivery
      • Oral Drug Delivery
      • Pulmonary Drug Delivery
      • Topical Drug Delivery
      • Transmucosal Drug Delivery

      Target Audience

      • Pharmaceutical Manufacturers : UK and international pharmaceutical companies need detailed market analysis to guide product development, manufacturing investments, and market entry strategies specific to the UK healthcare system.
      • Healthcare Investors : Private equity firms, venture capitalists, and institutional investors require UK market data to evaluate investment opportunities, assess portfolio companies, and identify growth prospects in drug delivery.
      • Medical Device Companies : Device manufacturers developing drug delivery systems need UK-specific market insights to understand demand, regulatory pathways, and partnership opportunities with pharmaceutical firms.
      • Healthcare Consultants : Management consulting firms and healthcare advisors require accurate UK market data to support client strategy development, competitive analysis, and market entry recommendations.
      • NHS and Policy Makers : Healthcare administrators and government officials need market intelligence to inform procurement decisions, budget planning, and policy development for pharmaceutical drug delivery services.

      Key Companies in the UK Pharmaceutical Drug Delivery Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanyOral drug delivery (solid & liquid dosage),Injectable and parenteral drug delivery,Topical, transdermal, and transdermal patch,
      KINDRED HEALTHCARE INC.United StatesPrivate CompanyInjectable drug delivery (acute and chronic in LTAC),Oral drug delivery (maintenance and step-down therapy),Pulmonary and inhaled delivery,
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyOral drug delivery automation (solid dose and packaging),Injectable and parenteral drug delivery automation,Topical, transdermal patch, and transdermal-related automation,
      APTARGROUP INCUnited StatesPublic CompanyNasal drug delivery systems,Pulmonary and inhalation devices,Injectable elastomeric components,
      CONSORT MEDICALUnited KingdomPrivate CompanyInhalation & Pulmonary Devices,Injectable & Autoinjector Systems,Nasal & Ocular Devices,
      JABILUnited StatesPublic CompanyInjectable drug delivery (including autoinjectors and pens),Pulmonary and inhalation devices,Oral and solid-dose related packaging/devices,
      MERCK KGAAGermanyPublic CompanyInjectable and biologic delivery (excipients, single-use systems, resins, related therapies),Oral and topical delivery (excipients, analytical reagents, related therapies),Ocular, nasal, transmucosal & implantable,
      TAKEDA PHARMACEUTICAL COMPANYJapanPublic CompanyOral drug delivery (small molecules and targeted agents),Injectable and subcutaneous biologics,Topical, ocular, nasal, and transmucosal & implantable,
      VECTURA GROUP PLCUnited KingdomPrivate CompanyPulmonary (inhalation devices and formulations),Nasal and ocular delivery,Oral and injectable enabling technologies,
      SANOFIFrancePublic CompanyInjectable drug delivery (incl. insulin, biologics, vaccines),Oral drug delivery (small molecules for CV, diabetes, immunology),Topical, transdermal, and transdermal patch,
      NOVO NORDISK A/SDenmarkPublic CompanyInjectable (insulin, GLP-1, growth hormone) via pens and smart pens,Oral GLP-1 and other oral metabolic formulations,Injectable rare disease therapies and hormone replacement,
      GLENMARK PHARMACEUTICALS LTD.IndiaPublic CompanyOral drug delivery (solids and liquids),Injectable and biologic formulations,Topical and dermatology formulations,
      VIATRIS INCUnited StatesPublic CompanyOral solid dose (tablets, capsules),Injectables (including complex injectables),Pulmonary / inhalation (e.g., Wixela Inhub, Breyna, Yupelri),
      BRISTOL-MYERS SQUIBB COMPANYUnited StatesPublic CompanyInjectable & Infusion (incl. IV/SC oncology and immunology),Oral (oncology, cardiovascular, immunology, neuroscience),Other routes (topical, ocular, nasal, pulmonary, transdermal/implantable),
      XERIS PHARMACEUTICALS, INC.United StatesPublic CompanyInjectable – Diabetes / Hypoglycemia (Gvoke),Injectable – Endocrine / Cushing’s (Recorlev),Oral – Periodic Paralysis (Keveyis),

      PATHEON INC

      Patheon Inc is a private pharmaceutical company based in the Netherlands with 9,100 employees. The company operates in the pharmaceutical manufacturing and contract development sector.

      KINDRED HEALTHCARE INC.

      Kindred Healthcare Inc is a private healthcare services company founded in 1985 and headquartered in the United States, employing 64,200 people. The company operates in the healthcare delivery and related services industry.

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc is a publicly traded Canadian company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems manufacturing.

      APTARGROUP INC

      Aptar Group Inc is a publicly traded company founded in 1992 and headquartered in the United States with 14,000 employees. The company manufactures dispensing and sealing solutions for pharmaceutical and consumer products.

      CONSORT MEDICAL

      Consort Medical is a private medical device company founded in 1938 and based in the United Kingdom with 2,000 employees. The company develops and manufactures drug delivery systems and medical devices.

      JABIL

      Jabil is a publicly traded electronics manufacturing services company founded in 1966 and headquartered in the United States with 135,000 employees. The company provides manufacturing solutions across multiple industries including healthcare and pharmaceuticals.

      MERCK KGAA

      Merck KGaA is a publicly traded pharmaceutical and chemical company founded in 1668 and based in Germany with 59,077 employees. The company operates globally in pharmaceuticals, life sciences, and performance materials.

      TAKEDA PHARMACEUTICAL COMPANY

      Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. The company develops and manufactures pharmaceutical products globally.

      VECTURA GROUP PLC

      Vectura Group PLC is a private pharmaceutical company founded in 1997 and based in the United Kingdom with 502 employees. The company specializes in respiratory drug delivery technologies.

      SANOFI

      Sanofi is a publicly traded pharmaceutical company founded in 1994 and headquartered in France with 74,846 employees. The company develops and manufactures a broad range of pharmaceutical products globally.

      NOVO NORDISK A/S

      Novo Nordisk A/S is a publicly traded pharmaceutical company founded in 1923 and based in Denmark with 67,900 employees. The company specializes in diabetes care, obesity, and other therapeutic areas.

      GLENMARK PHARMACEUTICALS LTD.

      Glenmark Pharmaceuticals Ltd is a publicly traded pharmaceutical company founded in 1977 and based in India with 15,800 employees. The company develops and manufactures generic and specialty pharmaceutical products.

      VIATRIS INC

      Viatris Inc is a publicly traded pharmaceutical company founded in 1961 and headquartered in the United States with 30,000 employees. The company manufactures and distributes generic and specialty pharmaceutical products.

      BRISTOL-MYERS SQUIBB COMPANY

      Bristol-Myers Squibb Company is a publicly traded pharmaceutical company founded in 1887 and headquartered in the United States with 32,500 employees. The company develops and manufactures innovative pharmaceutical products.

      XERIS PHARMACEUTICALS, INC.

      Xeris Pharmaceuticals, Inc is a publicly traded pharmaceutical company founded in 2005 and headquartered in the United States with 435 employees. The company develops and commercializes specialty pharmaceutical products.

      Reasons to Buy this Report

      • Market-Specific Insights : Gain detailed understanding of UK-specific market dynamics, regulatory requirements, and competitive landscape distinct from broader European or global markets, enabling targeted business strategy development.
      • Accurate Forecasting : Access precise market size projections and CAGR data for the UK through 2031, supporting informed investment decisions, resource allocation, and long-term business planning in the region.
      • Regulatory Intelligence : Understand UK-specific regulatory pathways, MHRA approval processes, and post-Brexit compliance requirements essential for product launches and market entry strategies in the pharmaceutical sector.
      • Competitive Positioning : Identify UK market opportunities, competitive gaps, and emerging trends in drug delivery technologies to position products effectively against local and international competitors.
      • Stakeholder Alignment : Present credible, region-specific market data to investors, board members, and partners to justify expansion decisions, partnerships, and capital investments in the UK pharmaceutical market.

      Frequently asked questions

      What is the current size of the US pharmaceutical drug delivery market?

      The US pharmaceutical drug delivery market is estimated at $321.81 billion in 2026 and is projected to reach $338.09 billion by 2031.

      What is the growth rate of the US pharmaceutical drug delivery market?

      The US pharmaceutical drug delivery market is expected to grow at a compound annual growth rate (CAGR) of 1.9% from 2026 to 2031.

      What factors are driving growth in the US pharmaceutical drug delivery market?

      The US market is driven by aging demographics, increasing prevalence of chronic diseases, strong healthcare infrastructure, significant R&D investments, and growing demand for personalized medicine and advanced delivery technologies.

      How does the US market compare to global pharmaceutical drug delivery trends?

      The US market grows at 1.9% CAGR, slower than the global average of 6.3%, reflecting market maturity; however, the US remains a leader in innovation and advanced delivery platform development.

      What delivery technologies are most prevalent in the US market?

      The US market encompasses biologics, injectables, oral formulations, and emerging personalized medicine platforms, supported by advanced manufacturing capabilities and regulatory approval pathways.

      RESEARCH METHODOLOGY

      This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

      Secondary Research

      This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the veterinary imaging market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

      Primary Research

      In the primary research process, a range of sources from the supply and demand sides were used to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the pharmaceutical drug delivery market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes, and contract research organizations.

      A breakdown of the primary respondents is provided below:

      Pharmaceutical Drug Delivery Market Size, and Share

      Note: C-level executives include CEOs, COOs, CTOs, and VPs. Other designations include sales, marketing, and product managers.

      Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the pharmaceutical drug delivery market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

      Pharmaceutical Drug Delivery Market : Top-Down and Bottom-Up Approach

      Pharmaceutical Drug Delivery Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

      Market Definition

      Pharmaceutical drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits, such as ease of use, convenience, and patient compliance. Drug delivery technologies are used for the targeted delivery and/or controlled release of therapeutic agents.

      Key Stakeholders

      • Pharmaceutical manufacturing companies
      • Original equipment manufacturing companies
      • Suppliers and distributors of pharmaceutical products and medical devices
      • Healthcare service providers
      • Teaching hospitals and academic medical centers
      • Health insurance players
      • Government bodies/municipal corporations
      • Regulatory bodies
      • Medical research institutes
      • Business research and consulting service providers
      • Venture capitalists
      • Market research and consulting firms

      Report Objectives

      • To describe and forecast the global pharmaceutical drug delivery  market, by route of administration, application, facility of use, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
      • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
      • To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, Netherlands, Denmark, Sweden, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa [Turkey, GCC Countries (Saudi Arabia, the UAE and Rest of GCC) and Rest of Middle East & Africa]
      • To profile the key market players and comprehensively analyze their market shares and core competencies2
      • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global pharmaceutical drug delivery  market

      Customization Options

      With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global pharmaceutical drug delivery market report.

      Product Analysis

      • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

      Company Information

      • Detailed analysis and profiling of additional market players (up to 5 players)

      Geographic Analysis

      • Further breakdown of the Rest of Europe pharmaceutical drug delivery  market into Austria, Switzerland, Finland, Sweden, Poland, and Portugal, among other countries
      • Further breakdown of the Rest of Asia Pacific pharmaceutical drug delivery   market into Vietnam, Philippines, Singapore, Malaysia, and Indonesia, among other countries
      •  Further breakdown of the Rest of Latin America pharmaceutical drug delivery market into Chile and Colombia, among other countries.

      Country-Level Volume Analysis By Product

      • Quantifies volumes by major service types for selected countries to show demand patterns. Product Type Market Share Analysis (Top 5 Players).

      By Route Of Administration Market Share Analysis (Top 5 Players)

      • Route of Administration Market Share Analysis (Top 5 Players).

      Any Consult/Custom Requirements As Per Client Requests

      • Provides tailored analyses, datasets, and deliverables based on specific client briefs..

      Get the Full Pharmaceutical Drug Delivery Market Report

      Full forecast, segment splits, and company analysis for all Pharmaceutical Drug Delivery Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status